…I thought [Dr. Dietrich’s] comments about ACH-1625 behaving more like a nuke than a PI in terms of resistance profile were interesting.
This was more propaganda by Dr. Dietrich, IMO, although perhaps not as outrageous as his claims about qD dosing of ribavirin (#msg-50207074). To date, there’s no empirical evidence that ACH-1625 has a significantly higher barrier to resistance than other PI’s—it merely has a very long half-life, which is more of a negative than a positive (#msg-46185187).
ACHN’s having a hired hand like Dr. Dietrich on the conference call suggests to me that ACHN itself is not confident about the commercial outlook for ACHN-1625. Perhaps prospective partners have passed on licensing the drug because it has a very long half-life. If this is the case, ACHN should be up-front about it instead of engaging a shill like Dietrich to make wildly bullish assertions about ACH-1625 that have no basis in fact.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.